Lightnews — Scholar-powered news

Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - OncoDaily

1 3

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 14d

Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series / cancer, International Cancer Patient Coalition,

When AI rejects your grant proposal: algorithms are helping to make funding decisions

2 5

Vivek Subbiah, MD @viveksubbiah.bsky.social · 10d

⭐️When AI rejects your grant proposal: algorithms are helping to make funding decisions
A foundation using an AI tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust
www.nature.com/articles/d41...

A Spanish foundation using an artificial-intelligence tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust.

Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review

1 1 2

Reposted by Vivek Subbiah, MD

Gregory Riely @rielymd.bsky.social · 16d

Appropriately critical commentary on cochrane reviews as the apply to matched targeted therapy by @viveksubbiah.bsky.social Journal of Clinical Oncology ascopubs.org/doi/full/10....

ascopubs.org

3 2

Reposted by Vivek Subbiah, MD

Syed Mohi Ahmed, MD, PhD @smohahm.bsky.social · Aug 12

PFS benefit noted with adagrasib

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.

10 Must-Read Posts in Immuno-Oncology This Week - OncoDaily

1 1 3

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Aug 24

10 Must-Read Posts in Immuno-Oncology This Week

@viveksubbiah.bsky.social @jiajennyliu.bsky.social @gerryhanna.bsky.social @drjnaidoo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #ImmuneOncology

10 Must-Read Posts in Immuno-Oncology This Week / Alex Menzies, Alexander Van Akkooi, AndrewFurness, cancer, chemoimmunotherapy, Christian Blank, David

Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma - OncoDaily

1 10

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Sep 4

Nature Medicine Study on Molecular Profiling in Meningioma - @viveksubbiah.bsky.social

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine

Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma / Alexander P. Landry, Andrew Ajisebutu, cancer, Chloe Gui, Farshad Nassiri, Gelareh

Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too - OncoDaily

1 6

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 25d

Rare Cancers Deserve Breakthroughs Too - Vivek Subbiah

@viveksubbiah.bsky.social @conquercancer.bsky.social

oncodaily.com/blog/rare-ca...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too / American Society of Clinical Oncology, ASCO, cancer, Conquer Cancer, Conquer Cancer the ASCO

Top Articles Suggested by Vivek Subbiah - OncoDaily

1 4

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 24d

Top Articles Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top Articles Suggested by Vivek Subbiah / cancer, Nature, NEJM, OncoDaily, Oncology, Vivek Subbiah

Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

1 3

Reposted by Vivek Subbiah, MD

JAMA Oncology @jamaoncology.com · 20d

🔊 Listen to Jiyoung Ahn, PhD, of New York University, discuss with @viveksubbiah.bsky.social, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic #cancer.

Listen now: ja.ma/41Vzuh9

Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD.

ja.ma

1 1

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 17d

Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - Vivek Subbiah

@viveksubbiah.bsky.social @fredhutch.org

oncodaily.com/career/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - OncoDaily

Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center / cancer, Fred Hutch Cancer Center, OncoDaily,

Top 5 Articles of the Week Suggested by Vivek Subbiah - OncoDaily

1 5

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · 17d

Top 5 Articles of the Week Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top 5 Articles of the Week Suggested by Vivek Subbiah / cancer, Cancer Discovery, Nature, OncoDaily, Oncology, Sarah Cannon Research Institute, Vivek Subbiah

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

2 5

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study

1 2 5

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study - The Lancet Oncology www.thelancet.com/journals/lan...

Within hypermutated colorectal cancer, younger patients exhibited a higher mutational burden than older patients. Our study reveals an abnormal accumulation of distinct somatic mutations in hypermutat...

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

3 5

Vivek Subbiah, MD @viveksubbiah.bsky.social · Aug 11

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol - The Lancet Oncology www.thelancet.com/journals/lan...

We did not find significant evidence of an overall survival benefit of adding metformin to standard of care in the overall population of patients with metastatic hormone-sensitive prostate cancer. The...

Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know - OncoDaily

3

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jul 21

What is Missing to Fully Harness Precision Medicine and Transform Cancer Care - Vivek Subbiah
@viveksubbiah.bsky.social
@natmed.nature.com

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PrecisionMedicine

Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know / cancer, Nature Reviews Bioengineering, OncoDaily, Oncology, Vivek

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification - OncoDaily

2 5

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jul 7

It’s Time We Evolve WHO Cancer Classification - Vivek Subbiah
@viveksubbiah.bsky.social
@who.int

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerClassification #WHO

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Happy 4th everyone! Delighted to share with the our comment just published in t...

Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options - OncoDaily

2 8

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jul 5

How Clinical Trials Offer Hope for Those Facing Limited Options - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/clinica...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrial #Sarcoma #SarcomaAwarenessMonth

Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options / cancer, OncoDaily, Oncology, Sarah Cannon Research Institute, Sarcoma

Tissue-agnostic cancer therapies: promise, reality, and the path forward - Nature Communications

1 5

Reposted by Vivek Subbiah, MD

Vivek Subbiah, MD @viveksubbiah.bsky.social · May 29

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward
@natcomms.nature.com @ascocancer.bsky.social #ASCO25
www.nature.com/articles/s41...

Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...

Vivek Subbiah: Cancer Isn’t Just a Human Disease - It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - OncoDaily

3 15

Reposted by Vivek Subbiah, MD

Vivek Subbiah, MD @viveksubbiah.bsky.social · Apr 8

🚨 Hot off the press! 🚨 The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology 🧬🏥
www.annalsofoncology.org/article/S092...

1 3 10

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jun 22

Cancer Isn’t Just a Human Disease – It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Medicine #Health

Vivek Subbiah: Cancer Isn’t Just a Human Disease - It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs / Amy M. Boddy,

25 Posts Not to Miss from EHA 2025: - OncoDaily

1 5

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jun 17

25 Posts Not to Miss from EHA 2025
@nicogagelmann.bsky.social @talhabadarmd.bsky.social @majorajay.bsky.social @vincentrk.bsky.social @viveksubbiah.bsky.social @nejm.org

oncodaily.com/societies/eh...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA2025 #EHA25

The European Hematology Association (EHA 2025) congress is officially underway in Milan. From June 12 to 15, hematology professionals from

Vivek Subbiah: Why Every Rare Cancer Patient Deserves Molecular Profiling? - OncoDaily

3 9

Reposted by Vivek Subbiah, MD

OncoDaily @oncodaily.bsky.social · Jun 15

Why Every Rare Cancer Patient Deserves Molecular Profiling? - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/insight/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #RareCancers #MolecularProfiling

Vivek Subbiah: Why Every Rare Cancer Patient Deserves Molecular Profiling? / Bettina Ryll, Branko Cuglievan, cancer, clinical trials, FDA, Howard A. Burris

Tissue-agnostic cancer therapies: promise, reality, and the path forward - Nature Communications

4 15

Reposted by Vivek Subbiah, MD

@doublewhammied @doublewhammied.bsky.social · May 29

Super interesting.

"Tissue-agnostic #cancer therapies promise 2 revolutionize oncology by targeting molecular drivers. [A] study of nearly 300K tumors found 21.5% w/tissue-agnostic indications. Despite 9 #FDA approvals, real-world implementation challenges ..." 1/2 #CanSky #OncSky #ASCO25

Vivek Subbiah, MD @viveksubbiah.bsky.social · May 29

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward
@natcomms.nature.com @ascocancer.bsky.social #ASCO25
www.nature.com/articles/s41...

Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...

Tissue-agnostic cancer therapies: promise, reality, and the path forward - Nature Communications

1 1 4

Vivek Subbiah, MD @viveksubbiah.bsky.social · May 29

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward
@natcomms.nature.com @ascocancer.bsky.social #ASCO25
www.nature.com/articles/s41...

Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...